| Literature DB >> 30089486 |
Masato Hayashi1, Hirofumi Kawakubo2, Shuhei Mayanagi1, Rieko Nakamura1, Koichi Suda1, Norihito Wada1, Yuko Kitagawa1.
Abstract
BACKGROUND: Inflammatory myofibroblastic tumor is an uncommon soft tissue neoplasm rarely reported in the stomach. CASEEntities:
Keywords: Combined laparoscopic and endoscopic gastric wedge resection; Inflammatory myofibroblastic tumor; Stomach
Mesh:
Year: 2018 PMID: 30089486 PMCID: PMC6083513 DOI: 10.1186/s12957-018-1460-0
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1a Endoscopy reveals a flat protrusion in the lesser curvature of lower third of the stomach. b Endoscopic ultrasound shows the tumor thickening the second and third layers of the stomach wall. c Computed tomography (CT) scanning shows the thickened wall at the angle of the stomach (white arrow), but no evidence of tumor metastasis. d Positron emission tomography-CT shows no evidence of tumor metastasis or abnormal uptake in the tumor
Fig. 2a The tumor circumference is marked to ensure an approximately 0.5-cm margin from the tumor edge using electrocautery. b Interoperative image showing the stomach after the seromuscular dissection was performed using a laparoscopic electrocautery scalpel. c The specimen is pulled up before performing full-thickness resection with a laparoscopic stapling device. d The seromuscular defect is sutured using a hand-sewn technique to avoid exposure of the staple line
Fig. 3a, b Spindle tumor cells are present in the gastric wall from the submucosa to the serosa accompanied by myxoid changes and collagen fibers in the stroma (H&E; × 10, × 100). c, d The tumor cells are strongly immunopositive for anaplastic lymphoma kinase (× 10, × 100)
Clinicopathologic features and surgery method in 23 cases of inflammatory myofibroblastic tumor
| Age | |
| Range | 2–80 |
| Mean | 35.9 |
| Sex | |
| Male | 11 (47.8%) |
| Female | 12 (52.2%) |
| Tumor location | |
| Upper third | 10 (43.5%) |
| Middle third | 6 (26.1%) |
| Lower third | 5 (21.7%) |
| Unknown | 2 (8.7%) |
| Tumor size (cm) | |
| Range | 1.8–15 |
| Mean | 7.4 |
| Mitosis (HPF) | |
| Range | 1–2 |
| Mean | 1 |
| ALK | |
| Positive | 8 (34.8%) |
| Negative | 6 (26.1%) |
| Not available | 9 (39.1%) |
| Surgery | |
| Distal gastrectomy | 3 (13.0%) |
| Partial gastrectomy | 9 (39.1%) |
| Total gastrectomy | 1 (4.3%) |
| Wedge resection | 1 (4.3%) |
| Partial gastrectomy with other organ resection | 4 (17.4%) |
| Sleeve gastrectomy | 1 (4.3%) |
| Combined laparoscopic and endoscopic gastric wedge resection | 1 (4.3%) |
| EMR | 1 (4.3%) |
| Unknown and other | 2 (8.7%) |